Published in Hematology Week, January 8th, 2007
Analysis of data from this study showed that Promacta at 50 mg or 75 mg resulted in a positive trend in decrease in bleeding incidence (all grades) in adult patients with chronic idiopathic thrombocytopenic purpura (ITP), an autoimmune condition which results in low blood platelet counts and bleeding from the small blood vessels. These data were presented at the 48th Annual American Society of Hematology (ASH) meeting in Orlando, Florida.
The primary efficacy...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.